Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Cisplatin Induction Followed by Chemo-radiation/Surgery in Pancreatic Cancer
NCT00003332Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Jul 1997
- Primary completion
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in pancreatic cancer (PC), sponsored by NYU Langone Health. Primary endpoints: Response Rate at 8 weeks, Maximum Tolerated Dose at 14 weeks and 3 more. Started Jul 1997; status: completed.
02
Drugs
gemcitabinecisplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00003332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003332.